Form 4/A for NRXP NRX Pharmaceuticals, Inc.
Accepted 2022-06-02 00:00:00 ET · period of report 2022-06-01 · accession 0000921895-22-001874 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-06-02 | 2022-06-01 | NRXP | Javitt Jonathan C | Chief Scientist, Dir, 10% | P - Purchase | $0.58 | +100.0K | 146.3K | +216% | +$58.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-01 | P | A | 100,000 | $0.58 | 146,332 | D | — | — |